Capmatinib-induced interstitial lung disease: A case report

Unstructured abstract: Capmatinib, a highly specific MET inhibitor, was recently approved by the FDA for use in MET exon 14 skipping mutation-positive NSCLC. Although it is usually well tolerated, we describe the first case of a patient who incurred severe pneumonitis linked to this treatment.A 76 y...

Full description

Bibliographic Details
Main Authors: Kinan El Husseini, Nouha Chaabane, Audrey Mansuet-Lupo, Karen Leroy, Marie-Pierre Revel, Marie Wislez
Format: Article
Language:English
Published: Elsevier 2020-12-01
Series:Current Problems in Cancer: Case Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2666621920300247